Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Level I

Most favorable

Saves money and QALYs

Level II

More favorable

Costs<$10,000 per QALY saved

Level III

Favorable

Costs>$10,000 and<$100,000 per QALY saved

Level IV

Less favorable

Costs>$100,000 per QALY saved.

Seven candidate vaccines fall into the most favorable (I) category: those with which a vaccination strategy would save money. The Level I candidate vaccines are as follows (in alphabetical order):

  • cytomegalovirus (CMV) vaccine administered to 12-year-olds,

  • Group B streptococcus vaccine to be well-incorporated into routine prenatal care and administered to women during first pregnancy and to high-risk adults (at age 65 years and to people less than age 65 years with serious, chronic health conditions),

  • influenza virus vaccine administered to the general population (once per person every 5 years, or one-fifth of the population per year),

  • insulin-dependent diabetes mellitus therapeutic vaccine,

  • multiple sclerosis therapeutic vaccine,

  • rheumatoid arthritis therapeutic vaccine, and

  • Streptococcus pneumoniae vaccine to be given to infants and to 65-year-olds.

Nine candidate vaccines fall into the more favorable (II) category: those with which a vaccination strategy would incur small costs (less than $10,000) for each QALY gained. The Level II candidate vaccines are as follows (in alphabetical order):

  • chlamydia vaccine to be administered to 12-year-olds,

  • Helicobacter pylori vaccine to be administered to infants,

  • hepatitis C virus vaccine to be administered to infants,

  • herpes simplex virus vaccine to be administered to 12-year-olds,

  • human papillomavirus vaccine to be administered to 12-year-olds,

  • melanoma therapeutic vaccine,

  • Mycobacterium tuberculosis vaccine to be administered to high-risk populations,

  • Neisseria gonorrhea vaccine to be administered to 12-year-olds, and

  • respiratory syncytial virus vaccine to be administered to infants and to 12-year-old females.

Four candidate vaccines fall into the favorable (III) category: those with which a vaccination strategy would incur moderate costs (more than $10,000 but less than $100,000) per QALY gained. The Level III vaccine candidates are as follows (in alphabetical order):



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement